These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21635193)

  • 1. Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability.
    Panitch H; Applebee A
    Expert Opin Pharmacother; 2011 Jul; 12(10):1511-21. PubMed ID: 21635193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
    Lugaresi A
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR; Henney HR; Cohen R
    Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
    Dunn J; Blight A
    Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
    Egeberg MD; Oh CY; Bainbridge JL
    Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
    Pikoulas TE; Fuller MA
    Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR; Bienen EJ; Blight AR
    Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
    Fernandez O; Berger T; Hartung HP; Putzki N
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
    Korenke AR; Rivey MP; Allington DR
    Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapies for mobility disability in persons with multiple sclerosis.
    Baird JF; Sandroff BM; Motl RW
    Expert Rev Neurother; 2018 Jun; 18(6):493-502. PubMed ID: 29772185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.
    Berger JR
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S146-53. PubMed ID: 21761953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of dalfampridine in patients with multiple sclerosis.
    Ruck T; Bittner S; Simon OJ; Göbel K; Wiendl H; Schilling M; Meuth SG
    J Neurol Sci; 2014 Feb; 337(1-2):18-24. PubMed ID: 24290498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing dalfampridine efficacy in the physician's office.
    Raffel JB; Malik O; Nicholas RS
    Mult Scler; 2014 Jan; 20(1):24-6. PubMed ID: 23727943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained release oral fampridine in the treatment of multiple sclerosis.
    Kachuck NJ
    Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis.
    Weir S; Torkin R; Henney HR
    Curr Med Res Opin; 2013 Dec; 29(12):1627-36. PubMed ID: 23157467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
    Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
    Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
    Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
    Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
    Judge SI; Bever CT
    Pharmacol Ther; 2006 Jul; 111(1):224-59. PubMed ID: 16472864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines and best practices for appropriate use of dalfampridine in managed care populations.
    Miravalle AA
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S154-60. PubMed ID: 21761954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained-release fampridine for multiple sclerosis.
    Bever CT; Judge SI
    Expert Opin Investig Drugs; 2009 Jul; 18(7):1013-24. PubMed ID: 19548855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.